(TYRA) Tyra Biosciences, Inc. Business Model Canvas Research

Tyra Biosciences, Inc. depends on the FDA and other regulators for IND clearance, safety review, and study progression, which is critical in a preclinical and early clinical model. In 2025, every asset still had to pass these gates before reaching patients, so approval timing directly shaped pipeline speed and capital use.

• FDA IND review gates first-in-human dosing
• Safety signals can pause or stop trials
• Regulatory timing drives asset value

Tyra Biosciences, Inc. depends on capital providers because its 2018-founded, Carlsbad-based model is still R&D-heavy and pre-revenue. Public-market investors fund long drug-development timelines, where cash is needed well before product sales start.

• Founded in 2018
• Carlsbad, California HQ
• Pre-revenue biotech model
• External capital funds R&D

That makes equity markets and other backers a core partner, not just a funding source.

Tyra Biosciences, Inc. uses biomarker strategy to match patients to FGFR or RET alterations, which is central in precision oncology. FGFR2 fusions/rearrangements drive about 10% to 15% of intrahepatic cholangiocarcinoma, while RET fusions appear in roughly 1% to 2% of non-small cell lung cancers, so biomarker screening helps focus treatment and track response or resistance signals.

That lowers trial noise and supports faster go or stop calls on drug response.

• Match patients to FGFR or RET alterations
• Detect response and resistance signals
• Focus precision oncology trials

Tyra Biosciences is expanding beyond TYRA-300 into 4 programs: FGFR2-related intrahepatic cholangiocarcinoma, FGFR3-linked achondroplasia, RET kinase aberrations, and FGFR4-driven cancers. That widens the asset base, cuts dependence on one lead program, and opens more partnering paths across oncology and rare disease.

• 4 pipeline bets reduce single-asset risk.
• Oncology plus rare disease broadens partner appeal.

Tyra Biosciences, Inc. depends on Scientific IP because its selective kinase inhibition and structure-guided design know-how help protect the platform and candidate molecules. That patent moat supports defensibility and can raise licensing value for programs built on its cancer and genetic-disease pipeline.

• Protects platform chemistry
• Covers lead candidate molecules
• Supports licensing leverage

Tyra Biosciences, Inc. relies on a specialized team in medicinal chemistry, biology, translational science, and development to select targets and optimize leads fast. In small biopharma, this human capital is the key resource because one tight team can move a program from discovery to preclinical proof of concept with less handoff risk.

• Medicinal chemistry drives lead optimization.
• Biology and translational talent de-risk targets.

SNAP is built to speed structure-based drug design, so Tyra Biosciences, Inc. can test ideas faster and tighten the design cycle. In oncology, that speed matters because even a few months can affect differentiation, and Tyra was still advancing its 2025 pipeline with multiple FGFR programs.

• Faster design, faster learning
• Better candidate selection
• Useful in crowded oncology

Tyra Biosciences, Inc. is not tied to one disease or one target: its multi-program pipeline spans muscle-invasive bladder cancer, intrahepatic cholangiocarcinoma, achondroplasia, RET aberrations, and FGFR4 cancers. That spread across at least 5 active areas gives Tyra Biosciences, Inc. more shots at clinical wins, while lowering the risk that one setback derails the story.

• 5 pipeline areas
• Oncology plus rare disease
• More paths to data readouts

Tyra Biosciences, Inc. depends on steady regulator contact across 2025–2026, because safety updates, protocol amendments, and endpoint alignment must stay inspection-ready. The relationship is built on compliance and data, with every FDA discussion tied to evidence from ongoing clinical work.

• 2025–2026: continuous FDA dialogue
• Safety, protocol, endpoint updates
• Built on compliance and evidence

Tyra Biosciences, Inc. has no product sales yet, so partnering talks with larger biotech and pharma companies are a key customer relationship. These deals can bring upfront cash, shared development cost, and a sales network Tyra does not have in-house.

• Use licensing or co-development.
• Add capital before launch.
• Expand reach beyond Tyra.

In FY2025, Tyra Biosciences, Inc. used SEC filings, earnings materials, and investor presentations as its main investor channels to share clinical progress, safety risks, and trial plans. As a clinical-stage public company with no product revenue, these disclosures help keep capital access open and support future financing.

• SEC filings: risk and cash use
• Earnings: progress and guidance
• Decks: pipeline and milestones

Tyra Biosciences, Inc.’s corporate website is a direct, low-cost channel for pipeline news, company updates, and recruiting content, while also serving investors with filings and presentations. As a clinical-stage biotech with no approved products in 2025, the site is one of its main owned media tools for reaching candidates and the market.

• Direct access for candidates
• Pipeline and update hub
• Investor and recruiting use
• Low-cost messaging channel

Patients with RET rearranged during transfection kinase aberrations form a clear molecular segment for Tyra Biosciences, Inc. RET alterations are actionable in oncology and appear in about 1% to 2% of non-small cell lung cancers and 5% to 10% of papillary thyroid cancers, supporting a targeted therapy model and widening pipeline reach.

• RET is a validated oncology target
• Rare, biomarker-defined patient pool
• Supports precision treatment demand

Oncologists, urologists, and specialty hospitals are Tyra Biosciences, Inc.’s core clinical customers because they make the prescribing and treatment calls. In 2025, Tyra remained a clinical-stage company with 0 approved products, so adoption depends on these providers’ judgment, trial data, and access in hospital settings.

• Oncologists drive first-line adoption.
• Specialty hospitals shape access and referral flow.
• Clinical evidence is the key buying trigger.

Tyra Biosciences, Inc. G and A costs cover salaries, legal, finance, facilities, and public-company compliance, so they fund the corporate engine rather than lab work. As a Carlsbad, California Company, Tyra also carries local office overhead, and in a clinical-stage business these costs usually stay lower than R and D but still rise with SEC, audit, and listing demands.

• Pay staff and executives
• Cover legal and finance work
• Meet public-company rules
• Support Carlsbad office overhead

Tyra Biosciences, Inc. must keep funding patents, filings, and FDA/quality-system work, because biotech IP can lose value fast if it is not defended. For one IND-ready program, patent prosecution and regulatory prep can easily reach six figures, while a U.S. NDA filing fee alone was $4.6 million in FY2025.

• Patents protect TYRA-300 and platform IP.
• Filings add recurring legal and filing spend.
• Quality systems raise fixed compliance costs.

Tyra Biosciences, Inc. can earn royalties if partnered assets reach the market, turning upside into a longer-tail cash flow with little extra selling cost. In Tyra Biosciences, Inc.'s latest reported fiscal year, royalty revenue was $0, so this stream is still optionality, not current income.

• Market launch can trigger royalties.
• Low commercial burden, higher margin.
• Common biotech monetization model.

For Tyra Biosciences, research funding can bring in non-dilutive cash for specific translational projects, but it is usually much smaller than partnership revenue. In 2025, U.S. biotech SBIR/STTR awards commonly ranged from about $250,000 to $2,000,000 per phase, so this stream helps extend runway without issuing shares.

• Non-dilutive cash, no new shares
• Best for targeted early work
• Usually smaller than partner deals